Characterizing the Latent HIV-1 Reservoir in Patients with Viremia Suppressed on CART: Progress, Challenges, and Opportunities
Overview
Authors
Affiliations
Modern combination antiretroviral therapy (cART) can bring HIV-1 in blood plasma to level undetectable by standard tests, prevent the onset of acquired immune deficiency syndrome (AIDS), and allow a near-normal life expectancy for HIV-infected individuals. Unfortunately, cART is not curative, as within a few weeks of treatment cessation, HIV viremia in most patients rebounds to pre-cART levels. The primary source of this rebound, and the principal barrier to a cure, is the highly stable reservoir of latent yet replication-competent HIV-1 proviruses integrated into the genomic DNA of resting memory CD4+ T cells. In this review, prevailing models for how the latent reservoir is established and maintained, residual viremia and viremic rebound upon withdrawal of cART, and the types and characteristics of cells harboring latent HIV-1 will be discussed. Selected technologies currently being used to advance our understanding of HIV latency will also be presented, as will a perspective on which areas of advancement are most essential for producing the next generation of HIV-1 therapeutics.
Kae A, Nanfack A, Santoro M, Yagai B, Ambada G, Sagnia B BMJ Open. 2023; 13(10):e073672.
PMID: 37816567 PMC: 10565271. DOI: 10.1136/bmjopen-2023-073672.
Vaccine responses in ageing and chronic viral infection.
Rees-Spear C, McCoy L Oxf Open Immunol. 2023; 2(1):iqab007.
PMID: 36845567 PMC: 9914503. DOI: 10.1093/oxfimm/iqab007.
Role of CXCR5 CD8 T cells in human immunodeficiency virus-1 infection.
Gao L, Zhou J, Ye L Front Microbiol. 2022; 13:998058.
PMID: 36452930 PMC: 9701836. DOI: 10.3389/fmicb.2022.998058.
Macchi B, Frezza C, Marino-Merlo F, Minutolo A, Stefanizzi V, Balestrieri E Pathogens. 2020; 9(12).
PMID: 33322208 PMC: 7763350. DOI: 10.3390/pathogens9121047.